D-1013-2019 Class II Terminated
FDA drug recall D-1013-2019 was initiated by Mylan Institutional, Inc. (D.B.A. UDL Laboratories) on Jan 18, 2019 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval. The recall status is terminated (terminated Apr 29, 2020). Affected quantity: 10,281 UD cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Mar 27, 2019
- Initiation Date
- Jan 18, 2019
- Termination Date
- Apr 29, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 10,281 UD cartons
Product description
Alprazolam Tablets, USP, 0.25 mg, 10x10 per carton, Rx Only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 USA. NDC: 51079-788-20
Reason for recall
Failed Impurities/Degradation Specifications: Elevated levels of a known impurity detected during 6-month RT stability interval.
Distribution pattern
Nationwide USA and Puerto Rico
Code information
Lots: 3095198, 3096266, 3098776, EXP 05-2019
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1013-2019
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026